Search

everythinglearnresearchcommunity

for

Search:↓

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.

RTA 408 cream protects mice from radiation skin damage.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

Triptolide effectively and safely reduces actinic keratosis lesions in mice.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

Multitarget drugs are needed to better treat complex diseases.

The new antibody, TYHF-1, specifically targets certain hair-related structures.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

IL-17 and certain immune cells are linked to more severe alopecia areata.

Blocking interferon-gamma might help treat various autoimmune diseases.

Nano-PROTACs could improve drug targeting and delivery by using nanotechnology.

The treatment showed significant hair regrowth in alopecia areata patients without side effects.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Blocking mTORC1 reduces skin tumor growth in mice.

Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.